Resveratrol, pterostilbene, and dementia

• Published in: BioFactors (Oxford) 2018-01, Vol.44 (1), p.83-90
• Main Authors: Lange, Klaus W., Li, Shiming
• Format: Article
• Language: English
• Subjects: cognition; dementia; polyphenols; pterostilbene; resveratrol
• ISSN: 0951-6433; 1872-8081
• DOI: 10.1002/biof.1396

Resveratrol is a natural phytoestrogen with neuroprotective properties. Polyphenolic compounds including resveratrol exert in vitro antioxidant, anti‐inflammatory, and antiamyloid effects. Resveratrol and its derivative pterostilbene are able to cross the blood‐brain barrier and to influence brain activity. The present short review summarizes the available evidence regarding the effects of these polyphenols on pathology and cognition in animal models and human subjects with dementia. Numerous investigations in cellular and mammalian models have associated resveratrol and pterostilbene with protection against dementia syndromes such as Alzheimer's disease (AD) and vascular dementia. The neuroprotective activity of resveratrol and pterostilbene demonstrated in in vitro and in vivo studies suggests a promising role for these compounds in the prevention and treatment of dementia. In comparison to resveratrol, pterostilbene appears to be more effective in combatting brain changes associated with aging. This may be attributed to the more lipophilic nature of pterostilbene with its two methoxyl groups compared with the two hydroxyl groups of resveratrol. The findings of available intervention trials of resveratrol in individuals with mild cognitive impairment or AD do not provide evidence of neuroprotective or therapeutic effects. Future clinical trials should be conducted with long‐term exposure to preparations of resveratrol and pterostilbene with high bioavailability. © 2017 BioFactors, 44(1):83–90, 2018